PATENT CLAIM ANALYSIS

Application Number: 15907117
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["540", "461000"]

Abstract:
The present invention describes a new crystalline form of rifaximin, characterized in that it is a solvated form of rifaximin called rifaximin τ The invention also describes a process for the preparation of rifaximin τ, a pharmaceutical composition comprising said rifaximin form, and its use for treating inflammations and infections.

Claim (Index 2):
The form of rifaximin \u03c4, according to  claim 1 , characterized by a tetragonal crystal system, the space group is P41212 and the unit cell parameters are a=b=16.51 (1) \u212b; c=36.80(1) \u212b; \u03b1=\u03b2=\u03b3=90\u00b0; V=10027(1) \u212b3 or by a X-ray diffraction spectra with peaks at values of angles 2\u03b8\u00b10.1\u00b0 of 5.9\u00b0; 9.0\u00b0; 12.9\u00b0; 15.4\u00b0; 18.8\u00b0; 22.8\u00b0 and 23.4\u00b0.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 88.0
- Lexical Diversity: 1.54286
- Patent Class: 540.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15310436', '13935331', '11814628', '13582676', '14261337']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7099637075214583
- 35 USC 102 Novelty (BERT): 0.584576051114442
- Combined Prediction Score: 0.6974249418807567
- Mean Citation Score: 234.718832
- Max Citation Score: 411.19748
- Similarity Product: 296.00670835515024

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test